Evidence map›Paper›PMID 41145670›Full record

Trial reportLeukemia2026

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.

Mouhamad Khouja, Britta Kehden, Derek Blair, Christian Kuffer, Steve Wagner, Tim Versteegen, Philipp Nakov, Monika Brüggemann, Claudia Baldus, David Belada and 5 more

Registry-linked trialAbstract readClinical Trial, Phase IMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04134936 (A Phase Ib, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab in Addition to R-CHOP or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04134936 phase1completednot on this map

A Phase Ib, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab in Addition to R-CHOP or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - First-MIND

TypeinterventionalSponsorMorphoSys AGRan2019 to 2022Enrolled66ConditionsDiffuse Large B-cell LymphomaArmsTafasitamab, Tafasitamab plus lenalidomide
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mouhamad KhoujaSecond Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.ORCID 0000-0002-9892-9461
Britta KehdenSecond Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.
Derek BlairClinical Biomarkers & Companion Diagnostics, MorphoSys, a Novartis company Planegg, Planegg, Germany.
Christian KufferClinical Biomarkers & Companion Diagnostics, MorphoSys, a Novartis company Planegg, Planegg, Germany.
Steve WagnerClinical Development, MorphoSys, a Novartis company Planegg, Planegg, Germany.
Tim VersteegenSecond Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.
Philipp NakovSecond Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.
Monika BrüggemannSecond Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.
Claudia BaldusSecond Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.ORCID 0000-0002-0748-834X
David Belada4th Department of Internal Medicine - Hematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
Grzegorz S NowakowskiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-6955-9393
Anke SchilhabelSecond Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.
Nikos DarzentasSecond Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.
Christiane PottSecond Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany. c.pott@med2.uni-kiel.de.ORCID 0009-0005-9260-8340
EuroClonality-NGS Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The firstMIND trial (NCT04134936) evaluated the safety and efficacy of adding lenalidomide to R-CHOP+tafasitamab in the first-line treatment settings of patients with diffuse large B-cell lymphoma. To address response dynamics and the impact of measurable residual disease (MRD), we analyzed prospectively collected plasma samples from 56 study patients using the EuroClonality immunoglobulin gene (IG)-NGS assay. At baseline, disease-related clonotypes were identified in 50/56 (89%) patients by IG-NGS in cell-free (cf)DNA and/or FFPE samples. MRD markers were successfully identified in 49/52 (94%) cfDNA samples and 35/41 (85%) FFPE samples. Baseline cfDNA and circulating tumor (ct)DNA levels correlated with preclinical risk factors, and high cfDNA levels ≥3.35 log

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCirculating Tumor DNALymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overCyclophosphamideDoxorubicinFemaleFollow-Up StudiesHumansLenalidomideMaleMiddle AgedNeoplasm, ResidualBiomarkers, TumorCirculating Tumor DNACyclophosphamideDoxorubicinLenalidomidePrednisoneR-CHOP protocolRituximabVincristine

Identifiers

PMID41145670
PMCPMC12789008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.